Page 81 - Portuguese Journal - SPORL - Vol 61. Nº1

drugsatfda_docs/label/2021/103976s5239lbl.pdf
27. FDA. NUCALA® (Mepolizumab) Highlights of
Prescribing Information [Internet]. 2019 [cited 2022 mar
31]. p. 41. Disponível em: https://www.accessdata.fda.gov/
drugsatfda_docs/label/2022/761122s008,125526s019lbl.pdf
28. EMA. Dupixent: EPAR - Product Information [Internet].
Vol. 16, Netherlands Yearbook of International Law. 1985
[cited 2022 mar 31. p. 171. Disponível em: https://www.ema.
europa.eu/en/documents/product-information/dupixent-
epar-product-information_en.pdf
29. EMA. Xolair : EPAR - Product Information [Internet].
Vol. 16, Netherlands Yearbook of International Law. 1985
[cited 2022 mar 31]. p. 165. Disponível em: https://www.
ema.europa.eu/en/documents/product-information/
xolair-epar-product-information_en.pdf
30. EMA. Nucala : EPAR - Product Information [Internet].
Vol. 16, Netherlands Yearbook of International Law. 1985
[cited 2022 mar 31]. p. 62. Disponível em: https://www.ema.
europa.eu/en/documents/product-information/nucala-
epar-product-information_en.pdf
31. Weinstein MC, Torrance G, McGuire A. QALYs: The basics.
Value Health. 2009 Mar;12 Suppl 1:S5-9. doi: 10.1111/j.1524-
4733.2009.00515.x.
32. Rudmik L, Soler ZM, Mace JC, Schlosser RJ, Smith
TL. Economic evaluation of endoscopic sinus surgery
versus continued medical therapy for refractory chronic
rhinosinusitis. Laryngoscope. 2015 Jan;125(1):25-32. doi:
10.1002/lary.24916.
33. Scangas GA, Wu AW, Ting JY, Metson R, Walgama E,
Shrime MG. et al. Cost utility analysis of endoscopic sinus
surgery for chronic rhinosinusitis with and without nasal
polyposis. Laryngoscope. 2021 Jan;131(1):E26-E33. doi:
10.1002/lary.28648.
34. Scangas GA, Wu AW, Ting JY, Metson R, Walgama E,
Shrime MG. et al. Cost Utility analysis of dupilumab versus
endoscopic sinus surgery for chronic rhinosinusitis with
nasal polyps. Laryngoscope. 2021 Jan;131(1):E26-E33. doi:
10.1002/lary.28648.
35. Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer
L, Bousquet J. et al. EUFOREA consensus on biologics
for CRSwNP with or without asthma. Allergy. 2019
Dec;74(12):2312-2319. doi: 10.1111/all.13875.
36.Wu Q, Zhang Y, Kong W, Wang X, Yuan L, Zheng R. et
al. Which is the best biologic for nasal polyps: Dupilumab,
Omalizumab, or Mepolizumab? A network meta-analysis.
Int Arch Allergy Immunol. 2022;183(3):279-288. doi:
10.1159/000519228.

Volume 61 . Nº1 . March 2023 81